US Food and Drug Administration raised the possibility in an interview published Sunday that a future vaccine against the coronavirus might be given emergency approval before the end of trials designed to ensure its safety and effectiveness.A request for such extraordinary approval would have to come from the vaccine developer, Stephen Hahn told the Financial Times."If they do that before the end of Phase Three," which involves large-scale human testing, "we may find that appropriate.
We may find that inappropriate, we will make a determination."But Hahn insisted he was not acting under pressure from President Donald Trump, who has been pushing hard for a vaccine, saying one might be ready before US elections November 3."This is going to be.